Background: Escherichia coli sequence type (ST) 131-H30 is a globally important pathogen implicated in rising rates of multidrug resistance among E. coli causing extraintestinal infections. Previous studies have focused on adults, leaving the epidemiology of H30 among children undefined. Methods: We used clinical data and isolates from a case-control study of extended-spectrum cephalosporin-resistant E. coli conducted at 4 US children's hospitals to estimate the burden and identify host correlates of infection with H30. H30 isolates were identified using 2-locus genotyping; host correlates were examined using log-binomial regression models stratified by extended-spectrum cephalosporin resistance status. Results: A total of 339 extended-spectrum cephalosporin-resistant and 1008 extended-spectrum cephalosporin-susceptible E. coli isolates were available for analyses. The estimated period prevalence of H30 was 5.3% among all extraintestinal E. coli isolates (95% confidence interval [CI], 4.6%-7.1%); H30 made up 43.3% (81/187) of extended-spectrum β-lactamase (ESBL)-producing isolates in this study. Host correlates of infection with H30 differed by extended-spectrum cephalosporin resistance status: Among resistant isolates, age ≤5 years was positively associated with H30 infection (relative risk [RR], 1.83 [95% CI, 1.19-2.83]); among susceptible isolates, age ≤5 years was negatively associated with H30 (RR, 0.48 [95% CI, .27-.87]), while presence of an underlying medical condition was positively associated (RR, 4.49 [95% CI, 2.43-8.31]). Conclusions: ST131-H30 is less common among extraintestinal E. coli collected from children compared to reported estimates among adults, possibly reflecting infrequent fluoroquinolone use in pediatrics; however, it is similarly dominant among ESBL-producing isolates. The H30 subclone appears to disproportionately affect young children relative to other extended-spectrum cephalosporin-resistant E. coli.
Background: Escherichia coli sequence type (ST) 131-H30 is a globally important pathogen implicated in rising rates of multidrug resistance among E. coli causing extraintestinal infections. Previous studies have focused on adults, leaving the epidemiology of H30 among children undefined. Methods: We used clinical data and isolates from a case-control study of extended-spectrum cephalosporin-resistant E. coli conducted at 4 US children's hospitals to estimate the burden and identify host correlates of infection with H30. H30 isolates were identified using 2-locus genotyping; host correlates were examined using log-binomial regression models stratified by extended-spectrum cephalosporin resistance status. Results: A total of 339 extended-spectrum cephalosporin-resistant and 1008 extended-spectrum cephalosporin-susceptible E. coli isolates were available for analyses. The estimated period prevalence of H30 was 5.3% among all extraintestinal E. coli isolates (95% confidence interval [CI], 4.6%-7.1%); H30 made up 43.3% (81/187) of extended-spectrum β-lactamase (ESBL)-producing isolates in this study. Host correlates of infection with H30 differed by extended-spectrum cephalosporin resistance status: Among resistant isolates, age ≤5 years was positively associated with H30 infection (relative risk [RR], 1.83 [95% CI, 1.19-2.83]); among susceptible isolates, age ≤5 years was negatively associated with H30 (RR, 0.48 [95% CI, .27-.87]), while presence of an underlying medical condition was positively associated (RR, 4.49 [95% CI, 2.43-8.31]). Conclusions: ST131-H30 is less common among extraintestinal E. coli collected from children compared to reported estimates among adults, possibly reflecting infrequent fluoroquinolone use in pediatrics; however, it is similarly dominant among ESBL-producing isolates. The H30 subclone appears to disproportionately affect young children relative to other extended-spectrum cephalosporin-resistant E. coli.
Authors: Theresa Madigan; James R Johnson; Connie Clabots; Brian D Johnston; Stephen B Porter; Billie S Slater; Ritu Banerjee Journal: Clin Infect Dis Date: 2015-03-31 Impact factor: 9.079
Authors: James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira Journal: Clin Infect Dis Date: 2010-08-01 Impact factor: 9.079
Authors: James R Johnson; Veronika Tchesnokova; Brian Johnston; Connie Clabots; Pacita L Roberts; Mariya Billig; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Lance B Price; Maliha Aziz; Marie-Hélène Nicolas-Chanoine; Chitrita Debroy; Ari Robicsek; Glen Hansen; Carl Urban; Joanne Platell; Darren J Trott; George Zhanel; Scott J Weissman; Brad T Cookson; Ferric C Fang; Ajit P Limaye; Delia Scholes; Sujay Chattopadhyay; David C Hooper; Evgeni V Sokurenko Journal: J Infect Dis Date: 2013-01-03 Impact factor: 5.226
Authors: Ritu Banerjee; Ari Robicsek; Michael A Kuskowski; Stephen Porter; Brian D Johnston; Evgeni Sokurenko; Veronika Tchesnokova; Lance B Price; James R Johnson Journal: Antimicrob Agents Chemother Date: 2013-09-30 Impact factor: 5.191
Authors: Bente Olesen; Jakob Frimodt-Møller; Rikke Fleron Leihof; Carsten Struve; Brian Johnston; Dennis S Hansen; Flemming Scheutz; Karen A Krogfelt; Michael A Kuskowski; Connie Clabots; James R Johnson Journal: Antimicrob Agents Chemother Date: 2014-09-08 Impact factor: 5.191
Authors: James R Johnson; Marie-Hélène Nicolas-Chanoine; Chitrita DebRoy; Mariana Castanheira; Ari Robicsek; Glen Hansen; Scott Weissman; Carl Urban; Joanne Platell; Darren Trott; George Zhanel; Connie Clabots; Brian D Johnston; Michael A Kuskowski Journal: Emerg Infect Dis Date: 2012-04 Impact factor: 6.883
Authors: Lance B Price; James R Johnson; Maliha Aziz; Connie Clabots; Brian Johnston; Veronika Tchesnokova; Lora Nordstrom; Maria Billig; Sujay Chattopadhyay; Marc Stegger; Paal S Andersen; Talima Pearson; Kim Riddell; Peggy Rogers; Delia Scholes; Barbara Kahl; Paul Keim; Evgeni V Sokurenko Journal: mBio Date: 2013-12-17 Impact factor: 7.867
Authors: Latania K Logan; Jared R Rispens; Rachel L Medernach; T Nicholas Domitrovic; Andrea M Hujer; Steven H Marshall; Susan D Rudin; Nadia K Qureshi; Xiaotian Zheng; Mary K Hayden; Robert A Weinstein; Robert A Bonomo Journal: Pediatr Infect Dis J Date: 2021-01 Impact factor: 3.806